Seidman Gabriel, Atun Rifat
Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
BMJ Glob Health. 2017 Apr 13;2(2):e000243. doi: 10.1136/bmjgh-2016-000243. eCollection 2017.
Improving health systems performance, especially in low-resource settings facing complex disease burdens, can improve population health. Specifically, the efficiency and effectiveness of supply chains and procurement processes for pharmaceuticals, vaccines and other health products has important implications for health system performance. Pharmaceuticals, vaccines and other health products make up a large share of total health expenditure in low-income and middle-income countries (LMICs), and they are critical for delivering health services. Therefore, programmes which achieve cost savings on these expenditures may help improve a health system's efficiency, whereas programmes that increase availability of health products may improve a health system's effectiveness. This systematic review investigates whether changes to supply chains and procurement processes can achieve cost savings and/or improve the availability of drugs in LMICs.
Using the PRISMA guidelines for systematic reviews, we searched PubMed, Embase, CINAHL and the Health Economic Evaluation Database to identify.
We identified 1264 articles, of which 38 were included in our study. We found evidence that centralised procurement and tendering can achieve direct cost savings, while supply chain management programmes can reduce drug stock outs and increase drug availability for populations.
This research identifies a broad set of programmes which can improve the ways that health systems purchase and delivery health products. On the basis of this evidence, policymakers and programme managers should examine the root causes of inefficiencies in pharmaceutical supply chain and procurement processes in order to determine how best to improve health systems performance in their specific contexts.
改善卫生系统绩效,尤其是在面临复杂疾病负担的资源匮乏环境中,可改善人群健康状况。具体而言,药品、疫苗及其他卫生产品的供应链和采购流程的效率与成效对卫生系统绩效具有重要影响。在低收入和中等收入国家(LMICs),药品、疫苗及其他卫生产品在卫生总支出中占很大比例,且对提供卫生服务至关重要。因此,在这些支出上实现成本节约的项目可能有助于提高卫生系统的效率,而增加卫生产品可及性的项目可能会提高卫生系统的成效。本系统评价调查了供应链和采购流程的改变能否在低收入和中等收入国家实现成本节约和/或提高药品可及性。
我们按照系统评价的PRISMA指南,检索了PubMed、Embase、CINAHL和卫生经济评价数据库以进行识别。
我们识别出1264篇文章,其中38篇纳入我们的研究。我们发现有证据表明集中采购和招标可实现直接成本节约,而供应链管理项目可减少药品缺货情况并增加人群的药品可及性。
本研究确定了一系列可改善卫生系统采购和交付卫生产品方式的项目。基于这一证据,政策制定者和项目管理者应审视药品供应链和采购流程效率低下的根本原因,以便确定在其特定背景下如何最好地提高卫生系统绩效。